Citations

Clear

299 citation(s) found for "Solomon, B".

Challenges in Multiple Sclerosis Diagnosis: Misapplication and Misunderstanding of the McDonald Criteria (S6.001)
Solomon, Andrew , Pettigrew, Roman, Chahin, Salim , Krieger, Stephen, Weinshenker, Brian, Naismith, Robert T.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s6.001 Get It

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004
Maloney, David G. , Brander, Danielle M. , Dorritie, Kathleen , Soumerai, Jacob D. , Shah, Nirav N. , Nath, Rajneesh , Feldman, Tatyana , Solomon, Scott R. , Perna, Serena , Tuazon, Sherilyn A. , Ou, San-San, Rane, Neha, Wierda, William G. , Soumerai, Jacob D , Siddiqi, Tanya , Kenderian, Saad S. , Riedell, Peter A. , Fakhri, Bita , Stephens, Deborah M. , Ma, Shuo , Schuster, Stephen J. , Ou, San‐San , Wierda, William G.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 330-330

10.1182/blood-2023-179529 Get It

Background:Patients with R/R CLL/SLL who experience intolerance to or disease progression after Bruton tyrosine kinase inhibitor (BTKi) and venetoclax treatment have no established standard of care and poor outcomes, indicating a critical unmet need. Liso-cel, an autologous, CD19-directed, 4-1BB CAR T cell product, has demonstrated efficacy in large B-cell lymphoma and CLL/SLL. In the primary analysis of the phase 1/2, single-arm, multicenter TRANSCEND CLL 004 (NCT03331198) study, a single administration of liso-cel demonstrated rapid, deep, and durable responses and a manageable safety profile in patients with R/R CLL/SLL, including those with progression on previous BTKi and venetoclax failure (Siddiqi T, et al. Lancet 2023). The primary endpoint was met in the prespecified subset of efficacy-evaluable patients with disease progression on BTKi and venetoclax failure (primary efficacy analysis set [PEAS]) at a target dose of 100 × 10 6 CAR + T cells (null hypothesis: ≤ 5%) with the rate of complete response/remission (CR) and CR with incomplete marrow recovery (CRi) by an independent review committee (IRC) per 2018 International Workshop on CLL (iwCLL) criteria at 18.4% ( P = 0.0006). Here we report results from TRANSCEND CLL 004 with a median follow-up of 23.5 months. Methods: Patients must have received ≥ 2 prior lines of therapy, including a BTKi. Eligible patients received liso-cel at a target dose of either 50 × 10 6 (dose level [DL] 1) or 100 × 10 6 (DL2) CAR + T cells after lymphodepleting chemotherapy. The primary endpoint was CR/CRi in the PEAS at DL2. Key secondary endpoints were ORR and rate of undetectable MRD (uMRD; 10 −4 by next-generation sequencing) in blood. All null hypotheses were tested at the primary analysis and not retested in this analysis. Results:Of 137 leukapheresed patients, 118 received liso-cel (safety set), 97 (DL1 = 9; DL2 = 88) were efficacy evaluable, and 54 (DL1 = 4; DL2 = 50) were in the PEAS. In the safety set, median (range) age was 65 years (49-82), 83% had high-risk cytogenetics (del[17p], 42%; TP53 mutation, 47%; unmuted immunoglobulin heavy-chain variable gene, 47%; ≥ 3 chromosomal aberrations, 61%), median (range) lines of prior therapy was 5 (2-14), and all patients had prior BTKi. As of data cutoff (February 28, 2023), median (range) on-study follow-up was 23.5 months (0.4-59.6) for the safety set. In the PEAS at DL2, CR/CRi rate was 20% (95% CI, 10.0-33.7; Table 1). ORR was 44% (95% CI, 30.0-58.7). One patient who had best overall response (BOR) of partial response/remission (PR) at primary analysis had deepened to CR/CRi at 18 months without any additional therapy. Of 9 patients who had BOR of CR/CRi at the primary analysis, 8 had ongoing CR/CRi and 1 completed the study with the last assessment as CR/CRi. The uMRD rate was 64% (95% CI, 49.2-77.1) in blood and 60% (95% CI, 45.2-73.6) in marrow. Median (95% CI) duration of response was 35.3 months (12.4-not reached [NR]) and median duration of CR/CRi was NR. Median (95% CI) PFS was 11.9 months (5.7-26.2). Median (95% CI) OS was 30.3 months (15.0-NR). The efficacy outcomes were similar in the full population at DL2. Of 16 patients who had BOR of CR/CRi at primary analysis, 10 had ongoing CR/CRi. In the safety set, rates of any-grade and grade ≥ 3 treatment-emergent AEs were similar across age groups (Table 2). The rate of any-grade cytokine release syndrome (CRS) was 85% (grade 3, 8%; no grade 4/5) and neurological events (NE) was 45% (grade 3, 18%; grade 4, 1%; no grade 5); 69% received tocilizumab and/or corticosteroids for CRS/NEs. Median (range) time to onset and resolution was 4 days (1-18) and 6 days (2-37) for CRS and 7 days (1-21) and 7 days (1-83) for NEs, respectively. Prolonged cytopenia (grade ≥ 3 at Day 30 after liso-cel infusion), grade ≥ 3 infections, hypogammaglobulinemia, tumor lysis syndrome, second primary malignancy, and macrophage activation syndrome occurred in 54%, 18%, 15%, 11%, 9%, and 3%, respectively. Forty-five (33%) of 137 leukapheresed patients died after liso-cel infusion (disease progression, n = 27 [20%]; AE, n = 6 [4%]; other reasons, n = 12 [9%]). Conclusions: With longer follow-up, liso-cel continued to demonstrate durable CR/CRi, high uMRD rates, and a manageable safety profile in patients with heavily pretreated, high-risk R/R CLL/SLL. The safety results from longer follow-up were similar to those reported in the primary analysis with no new safety signals and were consistent across age groups.
Preliminary Results of the Oral CD73 Inhibitor, Oric-533, in Relapsed/Refractory Multiple Myeloma (RRMM)
Rodriguez, Cesar , Solomon, Scott R. , Paul, Barry , Patel, Meenal, Xu, Rongda , Daemen, Anneleen , Katewa, Subhash D. , Multani, Pratik S. , Nadeem, Omar , Wang, Jian , Junttila, Melissa R. , Gonsalves, Wilson I.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4761-4761

10.1182/blood-2023-173730 Get It

Background: Although recently available immune-based approaches in multiple myeloma produce high response rates, curative outcomes have not yet been achieved, which highlights the need for new agents that further activate the immune system without increasing toxicity. ORIC-533 is a highly potent and selective, orally bioavailable, small molecule inhibitor of CD73, an enzyme expressed by various cell types, including immune cells and which catalyzes the generation of adenosine from adenosine monophosphate (AMP) (Allard 2019). Adenosine itself is highly immunosuppressive, diminishing activity of a range of immune cell types, including T, NK, and dendritic cells (Young 2014). By blocking adenosine production from AMP via inhibition of CD73, ORIC-533 has demonstrated the ability to restore and enhance immune function. Multiple myeloma (MM) patient bone marrow (BM) contains multiple cell types that also express CD73, including immune cells, cancer-associated fibroblasts, mesenchymal stem cells, and endothelial cells (Allard 2019). Moreover, elevated adenosine levels in the MM BM niche correlate with disease progression (Horenstein 2016; Yang 2020). We have previously observed that CD73-mediated adenosine activity suppresses the cytolytic antitumor immune function in the MM BM milieu (Ray 2022). ORIC-533 treatment reduced adenosine production, overcame this immune suppression with evidence of restored DC-mediated priming and activated cytotoxic CD8 + T-cell function, and significantly enhanced immune cell cytolytic behavior against RRMM tumor cells in autologous patient ex vivo experiments (Junttila 2022), making ORIC-533 a potential immunotherapy for patients with MM. Methods: ORIC-533-01 (NCT05227144) is an ongoing i3+3 Phase 1b dose escalation study in patients with RRMM. The primary objectives are to determine single agent safety/tolerability and pharmacokinetics (PK) of ORIC-533 to select the RP2D. Pharmacodynamic assessments include measurement of CD73 functional activity in serum and BM, as well as enumeration of immune cell subsets and activation state in blood and BM. Patients are also evaluated for clinical efficacy using IMWG criteria. Results: As of 23 June 2023, 17 patients received ORIC-533 once daily across 4 dose levels (400 mg to 1600 mg). All patients were triple-class refractory, 88% were penta-refractory, and 59% also received prior anti-BCMA/CD3 bispecific therapy or anti-BCMA CAR-T therapy. Overall, ORIC-533 was very well tolerated, with 5 patients experiencing a total of 10 treatment-related adverse events (TRAEs). Fatigue was the only G3 AE and the only TRAE seen in more than 1 patient (1 event each of G3 and G2); all other events seen in 1 patient each, were G1 or G2 in severity, and of no specific system organ class. No dose limiting toxicities, no Grade ≥4 TRAEs, and no treatment-related serious adverse events have been observed. PK showed increased exposure with dose with a plasma half-life of ~24 hrs. Soluble CD73 enzymatic activity was nearly completely inhibited by C1D15 in serum of all patients across all dose levels, while the largest relative suppression in surface CD73 activity in BM cells was observed at the highest dose level. There was also evidence for increases in the abundance of circulating NK and CD8+ T cells after 1 treatment cycle, with preliminary evidence of enhanced CD8+ T-cell activation at the highest dose levels tested in both peripheral blood and BM. In addition, early evidence of single agent clinical activity was observed. Conclusions: ORIC-533 has demonstrated an acceptable safety profile and preliminary evidence of immune activation in a heavily pretreated RRMM patient population. Enrollment is ongoing and updated data will be presented.
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
Arnulf, Bertrand , Patel, Krina K. , Manier, Salomon , Vij, Ravi , Solomon, Scott R. , Abrahamsen, Ingerid Weum , Broijl, Annemiek , Chen, Christine , Delforge, Michel, Iida, Shinsuke , Truppel-Hartmann, Anna, Bhatnagar, Rashmi, Piasecki, Julia , Eliason, Laurie , Dhanda, Devender , Felten, Jasper, Caia, Andrea, Popa-McKiver, Mihaela, Abrahamsen, Ingerid Weum , Rodríguez‐Otero, Paula , Ailawadhi, Sikander , Cavo, Michèle , Nooka, Ajay K. , Callander, Natalie S. , Costa, Luciano J. , Bahlis, Nizar Jacques , Moreau, Philippe , Baz, Rachid , Jagannath, Sundar , Raje, Noopur , Scheid, Christof , Benjamin, Reuben , Pabst, Thomas , Berdeja, Jesús G. , Wu, Fan , Cook, Mark , Giralt, Sergio

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 1028-1028

10.1182/blood-2023-178933 Get It

Introduction A single ide-cel infusion showed significantly longer median progression-free survival (PFS) vs std regimens (13.3 vs 4.4 months [mo], HR 0.49, 95% CI 0.38-0.65, P < 0.001) with deep, durable responses in heavily pretreated TCE RRMM at an interim analysis (IA) of KarMMa-3 (NCT03651128); safety data were consistent with prior studies (Rodríguez-Otero et al. NEJM 2023). Ide-cel benefits were consistent across pts in high-risk subgroups and across 2-4 prior lines of therapy (Tx). Results of the preplanned final PFS analysis of KarMMa-3 with 12.3 mo additional follow-up are reported. Methods In the phase 3 KarMMa-3 trial, pts with RRMM who received 2-4 prior regimens, including an immunomodulatory agent, proteasome inhibitor, and daratumumab, and were refractory to last regimen were randomized 2:1 to ide-cel or a std regimen (DPd, DVd, IRd, Kd, or EPd). In the ide-cel arm, pts could receive ≤ 1 cycle of optional bridging Tx for disease control. Pts in the std regimens arm could receive ide-cel after confirmed disease progression (PD). The primary endpoint was IRC-assessed PFS in the ITT population; final PFS was planned to be analyzed with ~289 events. Key secondary endpoints were IRC-assessed overall response rate (ORR) and overall survival (OS); other secondary endpoints included complete response rate (CRR), duration of response (DOR), minimal residual disease (MRD) status, time to next anti-myeloma Tx (TTNT; time from randomization to next anti-myeloma Tx [MTx]), event-free survival (EFS; time from randomization to first PD, next MTx or any-cause death, whichever is first), PFS2 (time from randomization to second objective PD or any-cause death, whichever is first), safety, and health-related quality of life (QOL). Results Of 386 randomized pts (ide-cel, n = 254; std regimens, n = 132), 225 received ide-cel and 126 received a std regimen. Baseline characteristics were generally balanced. Median follow-up from randomization to data cutoff (April 28, 2023) was 30.9 mo (range 12.7-47.8). Ide-cel significantly improved median PFS (95% CI) vs std regimens (13.8 [11.8-16.1] vs 4.4 [3.4-5.8] mo), representing a 51% reduced risk of PD or death (HR 0.49, 95% CI 0.38-0.63; Figure); 18 mo PFS rates were 41% vs 19%, respectively. Ide-cel significantly improved ORR vs std regimens (71% vs 42%) with deeper (CRR 44% vs 5%; ≥CR and MRD negative status [sensitivity level 10 -5], 22% vs 1%), more durable responses (median DOR 16.6 vs 9.7 mo; Table). PFS and ORR benefits of ide-cel vs std regimens were consistent with the IA. Interim OS will be included in the presentation. In pts who received ide-cel (n = 225) or a std regimen (n = 126), median PFS (95% CI) was 15.7 (12.5-18.9) vs 4.4 (3.4-5.8) mo, respectively. In the ITT population, median TTNT, EFS, and PFS2 were numerically longer with ide-cel vs std regimens. Median (range) TTNT was 20.9 (16.6-24.2) vs 7.0 (5.3-8.5) mo. Median (95% CI) EFS was 13.3 (11.3-15.7) vs 3.9 (3.0-5.3) mo. Median PFS2 (95% CI) was 23.5 (18.4-27.9) vs 16.7 (12.2-20.3) mo; ide-cel was next MTx in 70 (53%) pts in the std regimens arm. In the treated population, grade (gr) 3/4 infections occurred in 66/249 (27%) pts in the ide-cel arm vs 25/126 (20%) in the std regimens arm. In the ide-cel safety population, any gr cytokine release syndrome occurred in 197/225 (88%) pts, gr ≥ 3 in 11 (5%); median time to first onset was 1 d (1-14), median duration was 4 d (1-51). Any gr investigator-identified neurotoxicity occurred in 34/225 (15%) pts, gr ≥ 3 in 7 (3%); median time to onset was 3 d (range 1-317); median duration was 2.5 d (range 1-252). Ide-cel continued to demonstrate durable, clinically meaningful improvements in pt-reported outcomes, including symptoms, functioning, and QOL vs std regimens. Conclusions In this final PFS analysis of KarMMa-3, significantly longer PFS was maintained with ide-cel; PD or death risk reduced by 51%; responses were deeper and more durable vs std regimens. CRR with ide-cel increased since the IA, indicating a deepening response, but were unchanged with std regimens. A single ide-cel infusion vs continuous treatment with std regimens resulted in longer median TTNT and PFS2, indicating improved long-term disease control. The ide-cel safety profile was consistent with previous reports, with no parkinsonism or Guillain-Barré syndrome reported. These data continue to support use of ide-cel in pts with TCE RRMM. Study support 2seventy bio and Celgene, a Bristol-Myers Squibb Company.
Abstract B055: Association between dietary patterns and occurrence of prostate cancer among Nigerian men: The CaPTC Familial Cohort Study
Bolajoko, Opeyemi , Oladoyinbo, Catherine, Lee, Daniel J. , Toye, Oluwaseyi, Fathi, Parisa , Bassey, Iya Eze , Jibrin, Paul, Ogo, Chidebere, Omonisi, Abidemi , Adeniji, Adebanji, Showunmi, Anthonia, Salako, Ayo, Nggada, Haruna Asura , Kaninjing, Ernie, Odedina, Folakemi T., Toye, Oluwaseyi, Turesky, Robert J. , Popoola, Ademola , Rotimi, Solomon O. , Fatiregun, Omolara , Faruk, Mohammed , Okoye, Ifeoma Joy

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 1, 2023 | Volume: 32 | Issue: 12_Supplement | Pages: B055-B055

10.1158/1538-7755.disp23-b055 Get It

Abstract Background: Prostate cancer (PCa) in men is, to date, the number one cause of death from cancer worldwide. PCa has been associated with a large number of lifestyle factors, including unhealthy dietary habits. In particular, diet and nutrition have been shown to play pivotal roles in PCa, and the habitual consumption of certain specific foods like meat cooked at very high temperatures has been implicated. However, this has not been documented among Black men. The aim of this study was to determine the association between dietary patterns and their association with the occurrence of prostate cancer. Method: This is a longitudinal multisite Prostate Cancer Transatlantic Consortium (CaPTC) familial cohort phase 2 study. Participants were Nigerian Black men between 35 and 70 years old who were willing to participate in the study over a 10-year period. For the food variety score, a score of 1 was given for each food item eaten weekly, and the aggregate food variety score was totaled and categorized as ≥54% very good, 45%–53% was good, 36%–44% fair, 18%–35% poor and <18% was very poor. Data were analyzed using descriptive statistics, such as frequency analyses. Chi-square analysis was used to evaluate dichotomous variables to compare groups based on demographic factors and the occurrence of PCa. Multivariate logistic regression was used to determine the specific predictors of the diagnosis of PCa with potential adjustment for the other demographic variables. P-values < 0.05 was set as significant. Results: A total of 780 participants were recruited, with 72.6% reporting no history of cancer. The median age was 47.00 (range: 21-97),16.5% have been diagnosed with Pca, and 1.5% were diagnosed with other Cancers. Age of cancer diagnosis showed that 21% were diagnosed at about 50 years. Participants’ fruit consumption showed that 28.4%, 29%, 39.5%, 23%, 31%, 28.7%, and 39.2, ate apples, mango, citrus, papaya, green banana, tomatoes, and watermelon, weekly, respectively. Fish was the most consumed protein source of animal origin irrespective of the cooking methods categories, such as boiling, frying, grilling, and smoking. The median food variety score was 20 (0-67), with 8.5%, 3.8%,49.3%, and 26.8% classified as good, very good, poor, and very poor, respectively. Multivariate analysis showed that the category of food variety score (P=0.0009), age (P<0.0001), and grilled fish consumption (P=0.0333) were found to be associated with Pca occurrence. Conclusions: The study showed that food variety score, age, and fish consumption were the correlates of prostate cancer occurrence in the population studied. Citation Format: Opeyemi O. Bolajoko, Catherine A. Oladoyinbo, Daniel Lee, Oluwaseyi Toye, Parisa Fathi, Robert Turesky, Ademola Popoola, Iya Bassey, Solomon Rotimi, Paul Jibrin, Chidebere Ogo, Abidemi Omonisi, Adebanji Adeniji, Anthonia Showunmi, Omolara Fatiregun, Ayo Salako, Haruna Nggada, Faruk Mohammed, Ifeoma Okoye, Ernie Kaninjing, Folakemi Odedina. Association between dietary patterns and occurrence of prostate cancer among Nigerian men: The CaPTC Familial Cohort Study [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B055.
Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial
Litwin, Sheldon E. , Komtebedde, Jan , Winkler, Sebastian , Solomon, Scott D. , Eicher, Jean-Christophe , Mazimba, Sula , Khawash, Rami, Sverdlov, Aaron L. , Hummel, Scott L. , Bugger, Heiko , Boenner, Florian, Hoendermis, Elke S., Čikeš, Maja , Demers, Catherine , Silva, Guillherme, Empel, Vanessa van , Pěnička, Martin, Cutlip, Donald E. , Leon, Martin B. , Kitzman, Dalane W. , Veldhuisen, Dirk J. van , Hummel, Scott L , Sverdlov, Aaron L , Seidler, Tim , Borlaug, Barry A. , Solomon, Scott David , Starling, Randall C. , Shah, Sanjiv J

Mayo Clinic

European Journal of Heart Failure | November 23, 2023 | Volume: 26 | Issue: 1 | Pages: 177-189

10.1002/ejhf.3092 | PMID 37989800 Get It

Abstract Aims Obesity is causally related to the development of heart failure with preserved ejection fraction (HFpEF) but complicates the diagnosis and treatment of this disorder. We aimed to determine the relationship between severity of obesity and clinical, echocardiographic and haemodynamic parameters in a large cohort of patients with documented HFpEF. Methods and results The REDUCE LAP-HF II trial randomized 626 patients with ejection fraction ≥40% and exercise pulmonary capillary wedge pressure (PCWP) ≥25 mmHg to atrial shunt or sham procedure. We tested for associations between body mass index (BMI), clinical characteristics, cardiac structural and functional abnormalities, physical limitations, quality of life and outcomes with atrial shunt therapy. Overall, 60.9% of patients had BMI ≥30 kg/m2. As the severity of obesity increased, symptoms (Kansas City Cardiomyopathy Questionnaire score) and 6-min walk distance worsened. More severe obesity was associated with lower natriuretic peptide levels despite more cardiac remodelling, higher cardiac filling pressures, and higher cardiac output. Lower cut points for E/e′ were needed to identify elevated PCWP in more obese patients. Strain measurements in all four chambers were maintained as BMI increased. Pulmonary vascular resistance at rest and exercise decreased with higher BMI. Obesity was associated with more first and recurrent heart failure events. However, there was no significant interaction between obesity and treatment effects of the atrial shunt. Conclusions Increasing severity of obesity was associated with greater cardiac remodelling, higher right and left ventricular filling pressures, higher cardiac output and increased subsequent heart failure events. Despite significant obesity, many HFpEF patients have preserved right heart and pulmonary vascular function and thus, may be appropriate candidates for atrial shunt therapy.
Effects of inhaled seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)
Tello, Khodr , Moles, Victor , Solomon, Scott D. , Cravets, Matt , Osterhout, Robin , Bruey, Jean‐Marie, Roscigno, Robert F., Aranda, R., Vachiéry, Jean‐Luc , McLaughlin, V.V., Zisman, Lawrence S. , Frantz, Robert P. , Solomon, Scott David , Osterhout, Robin E. , Badagliacca, Roberto , Benza, Raymond L. , Ghofrani, Hossein Ardeschir

Mayo Clinic

European Heart Journal | November 21, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.2012 Get It

Abstract Background Impaired RV-PA coupling portends a poor prognosis in PAH, and right ventricular free wall strain/systolic pulmonary artery pressure (RVFWS/sPAP) has been reported as a measure of RV-PA coupling. Furthermore, increased RVFWS and right atrial area (RAA), as well as decreased pulmonary artery compliance (PAC) are associated with increased mortality risk in PAH. Seralutinib is a novel, small molecule kinase inhibitor that targets PDGFR, CSF1R, and c-KIT administered via dry powder inhaler. TORREY, a phase 2, double-blind, randomised, placebo-controlled study of inhaled seralutinib in patients with PAH (NCT04456998) met its primary endpoint, demonstrating a significant reduction in pulmonary vascular resistance (PVR) from baseline (BL) to Week 24 compared to placebo. In addition, seralutinib significantly decreased NT-proBNP. Purpose To test the hypothesis that seralutinib would improve RVFWS/sPAP and other measures of right heart function after 24 weeks of treatment compared to placebo in the TORREY study. Methods Eighty-six patients with WHO Group 1 PH (Functional Class II, III), ages ≥18 years, pulmonary vascular resistance ≥400 dyne*s/cm5, and on stable PAH standard of care therapy (the majority of whom were on double and triple therapy with approved PAH medications) were enrolled. Right heart catheterisation (RHC) and full echocardiography were performed at BL and Week 24 and at BL, Week 12, and Week 24, respectively; both were analysed in a blinded central laboratory. To calculate RVFWS/sPAP, the pulmonary artery systolic pressure from RHC was used. PAC was calculated from RHC data with the formula (SV/(PAS-PAD)). Statistical analysis was performed using ANCOVA. Results At Week 24, the change in RVFWS/sPAP was lower in the seralutinib group compared to placebo (Table). The changes in RVFWS and RAA were lower in the seralutinib group vs placebo at Week 12 and Week 24 (Table). Change in NT-proBNP correlated with change in RAA (r = 0.43). At Week 24, change in PAC was greater in the seralutinib group (-0.02 ± 0.085 placebo, 0.19 ± 0.089 seralutinib; LSMD 0.22 (0.104) p = 0.04). There was no effect of seralutinib on left ventricular ejection fraction. Conclusion Treatment with seralutinib was associated with a significant reduction of RVFWS/sPAP. In addition, significant differences in RVFWS itself, RAA, and PAC were observed. These treatment effects support improved RV-PA coupling and right heart function. In conjunction with concordant reductions in PVR and NT-proBNP, these data suggest potential favourable effects of seralutinib in PAH. Seralutinib is in clinical development as a potential new treatment option for patients with PAH.
Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study
Claggett, Brian , Xu, Dongchu , Serrano‐Fernández, Pablo , Wandel, Simon , Zhao, Faye, Chutkow, William A., O’Donnell, Christopher J. , Prescott, Margaret F., Lefkowitz, Martin, Gimpelewicz, Claudio , Gou, Liangke , Redfield, Margaret M. , Rouleau, Jean L. , ZANNAD, Faiez, Solomon, Scott D. , Patel‐Murray, Natasha , Zhang, Luqing , Xu, Huilei , Healey, Margaret L. , Turner, Gordon M , Chen, Chien‐Wei , Yates, Denise P , Beste, Michael T , Desai, Akshay S , Jhund, Pardeep S. , Packer, Milton , Pfeffer, Marc Alan , Zannad, Faı̈ez , Zile, Michael R. , McMurray, John J.V. , Mendelson, Michael M , Solomon, Scott David , Cunningham, Jonathan W.

Mayo Clinic

Circulation | November 6, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.13828 Get It

Introduction: Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined. Goal: To identify serum proteins associated with risk for HF hospitalization (HFH) and cardiovascular (CV) death in patients with HFpEF, including proteins with differential associations with clinical outcomes in HFpEF compared to HFrEF. Methods: We measured serum levels of 4123 unique proteins in 1117 patients with HFpEF in the PARAGON-HF trial using a modified aptamer proteomic assay. Baseline protein concentrations significantly associated with total HFH and CV death were identified by recurrent events regression, accounting for multiple testing, adjusted for age, sex, treatment, and anticoagulant use, and compared to 2515 patients with HFrEF from the PARADIGM-HF and ATMOSPHERE trials. Results: We identified 288 proteins to be robustly associated with the risk of HFH and CV death (335 events over an average of 2.7 years of follow-up) in a HFpEF trial population. Proteins most strongly related to HFpEF outcomes included B2M, TIMP1, SERPINA4, and SVEP1 ( Figure ). Protein-outcome associations in patients with HFpEF did not markedly differ compared to HFrEF. Just 3 proteins (APOE, RTF1, and VWF) were differentially associated with outcomes between the HF subtypes (FDR <0.05). A proteomic risk score derived in HFpEF patients was not superior to a previous proteomic score derived in HFrEF nor to clinical risk factors, NT-proBNP, or high-sensitivity cardiac troponin. Conclusions: Numerous serum proteins linked to metabolic, coagulation, and extracellular matrix regulatory pathways were associated with worse HFpEF prognosis. SVEP1, a cell adhesion protein recently identified as a HFrEF prognosis biomarker, also strongly predicted risk in HFpEF. Our results demonstrate substantial similarities in serum proteomic risk markers across the EF spectrum.
Functional and anatomical connectivity predict brain stimulation’s mnemonic effects
Ezzyat, Youssef , Aronson, Joshua P. , Jobst, Barbara C. , Sheth, Sameer A. , Wanda, Paul A., Rizzuto, Daniel S. , Kahana, Michael J. , Jobst, Barbara , Kragel, James E. , Solomon, Ethan A. , Lega, Bradley Charles , Gross, Robert E. , Sperling, Michael R. , Worrell, Gregory A.

Mayo Clinic

Cerebral Cortex | November 2, 2023 | Volume: 34 | Issue: 1 | Pages: No page available

10.1093/cercor/bhad427 | PMID 38041253 Get It

Abstract Closed-loop direct brain stimulation is a promising tool for modulating neural activity and behavior. However, it remains unclear how to optimally target stimulation to modulate brain activity in particular brain networks that underlie particular cognitive functions. Here, we test the hypothesis that stimulation’s behavioral and physiological effects depend on the stimulation target’s anatomical and functional network properties. We delivered closed-loop stimulation as 47 neurosurgical patients studied and recalled word lists. Multivariate classifiers, trained to predict momentary lapses in memory function, triggered the stimulation of the lateral temporal cortex (LTC) during the study phase of the task. We found that LTC stimulation specifically improved memory when delivered to targets near white matter pathways. Memory improvement was largest for targets near white matter that also showed high functional connectivity to the brain’s memory network. These targets also reduced low-frequency activity in this network, an established marker of successful memory encoding. These data reveal how anatomical and functional networks mediate stimulation’s behavioral and physiological effects, provide further evidence that closed-loop LTC stimulation can improve episodic memory, and suggest a method for optimizing neuromodulation through improved stimulation targeting.